News | Left Atrial Appendage (LAA) Occluders | December 22, 2022

Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

The AcQCross Qx system combines the dilator and needle needed to perform left-atrial appendage closure procedures, eliminating the need to swap equipment mid-surgery while crossing into the left side of the heart. (Pixabay)

December 22, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced that the company has achieved the second milestone under the asset purchase agreement with Medtronic of its left-heart access portfolio with the submission for CE Mark of this portfolio under European Union (EU) Medical Device Regulations (MDR). This milestone triggers a $17 million earnout payment from Medtronic to Acutus.

“We are very pleased to have achieved this important milestone ahead of schedule. This submission is a critical step in our partnership with Medtronic, and we are confident that Medtronic will be able to accelerate adoption and positive impact on patient care and physician practice,” said David Roman, President & CEO of Acutus Medical. “In addition to positioning the left-heart access portfolio for long-term success in Europe, achieving this key milestone bolsters our financial position and enables Acutus to continue to focus on our differentiated mapping and therapy platform.”

Left-Heart Access Portfolio Sale
On June 30, 2022, Acutus completed the first closing of its previously announced sale of the Company’s left-heart access portfolio to Medtronic, which includes the AcQCross septal crossing devices, the AcQGuide MINI sheath and integrated crossing device, the AcQGuide FLEX Steerable Introducer with integrated crossing device, and the AcQGuide VUE steerable sheath.

Under the terms of the agreement, at the first closing, Medtronic paid cash consideration of $50 million to Acutus for, among other things, intellectual property rights to the Company’s left-heart access portfolio and certain equipment used in the manufacturing of these products. On October 31, 2022, Acutus completed the first major milestone in this transaction with OEM qualification and has now achieved the second major milestone of EU MDR filing. Starting January 28, 2023, Acutus will be eligible to receive four years of revenue-based earnouts.

For more information: https://www.acutusmedical.com/us/


Related Content

News | Left Atrial Appendage (LAA) Occluders

March 28, 2023 — The Society for Cardiovascular Angiography and Interventions (SCAI) and the Heart Rhythm Society (HRS) ...

Home March 28, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

February 27, 2023 — Conformal Medical, Inc. announced today the results from the CONFORMAL Early Feasibility Study (EFS) ...

Home February 27, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

September 12, 2022 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to ...

Home September 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

June 27, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home June 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

April 12, 2022 – Patients who had leakage to the left atrial appendage due to incomplete device sealing after left ...

Home April 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders
February 28, 2022 – Boston Scientific Corporation has announced positive results from a new analysis assessing real ...
Home February 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

Home November 08, 2021
Home
Feature | Left Atrial Appendage (LAA) Occluders

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

Home September 27, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

Home August 31, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

Home August 16, 2021
Home
Subscribe Now